Aktienanalyse zu Boston Scientific Corp (BSX)BSXBoston Scientific Corp

Boston Scientific Corporation is a global developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company's MedSurg segment includes Endoscopy, Urology, and Neuromodulation. Its Endoscopy business develops and manufactures devices to diagnose and treat a range of gastrointestinal conditions with less-invasive technologies. Its Urology business develops and manufactures devices to treat various urological conditions for both male and female anatomies, including kidney stones, benign prostatic hyperplasia, prostate cancer, erectile dysfunction, and incontinence. Its Neuromodulation business develops and manufactures devices to treat various neurological movement disorders and manage chronic pain. Its Cardiovascular segment includes Cardiology and Peripheral Interventions. The Cardiology includes interventional cardiology and vascular therapies (ICVT), watchman, cardiac rhythm management, and electrophysiology. It operates in the Healthcare sector (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry).

Boston Scientific Corp is currently priced at $42.73, which is below the average analyst price target of $48. However, the stock has seen a significant year-to-date decline of 54.88%, indicating potential recovery opportunities. The RSI is at 47.33, suggesting the stock is neither overbought nor oversold, which means it could be a good time to hold rather than buy or sell. The main risk is the insider selling activity, which has increased by 755.62% over the last month, indicating a lack of confidence from insiders.

24 analysts cover BSX: 18 rate it Buy, 6 Hold and 0 Sell. The average price target is 108.14.